non-hematologic toxicities included oral mucositis and diarrhea. No treatment-related cardiotoxicity or cerebellar toxicity was observed. Median overall survival duration was 4 months (range 1-30); at 10 months, the survival rate was 32%. Median relapse free survival duration was 8 months (range 4.5-29). In conclusion, our data support the use of GO in combination with conventional salvage chemotherapy in this very high risk category of patients and suggest that, for responders, allo-HSCT is feasible.

**P027**

A SIMPLE PROGNOSTIC SCORING SYSTEM FOR NEWLY DIAGNOSED ACUTE LEUKAEMIA PATIENTS WITH NON KARYOTYPE: A RETROSPECTIVE ANALYSIS ON 420 CASES

Malagola M.,1 Skert C.,1 Damiani D.,2 Candori A.,1 Tinibelli M.,1 Martinelli G.,1 Piccaluga P.,1 Paolini S.,1 Lauria F.,1 Bocchia M.,1 Gobbi M.,1 Pienni L.,1 Clavio M.,1 Miglino M.,1 Zaccaria A.,1 Zufeta E.,1 Mazza P.,1 Piccolo P.,1 Gugliotta L.1, Bonini A.,1 Visani G.,2 Bergonzi C.,1 Roccaro A.,1 Pelì A.,1 Fili C.,1 Turra A.,1 Battina F.,2 Fanin R.,2 Baccarani M.,1 Russo D.1

1Chair of Haematology, Unit of Blood Diseases and Cell Therapies, University of Brescia; 2Clinic of Haematology, University of Udine; 3Institute of Haematology and Medical Oncology “Serafogni”, University of Bologna; 4Chair of Haematology, University of Siena; 5Chair of Haematology, University of Genova; 6Division of Haematology, Ravenna; 7Division of Haematology, Taranto; 8Division of Haematology, Reggio Emilia; 9Division of Haematology, Pesaro, Italy

**Background.** Cytogenetics is the most important prognostic factor for acute myeloid leukaemia (AML), enabling to categorize AML patients in three risk categories: favourable, intermediate and unfavourable. The post-induction therapeutic strategy, including or not allogeneic-SCT, is not well established in patients with NK, who account for at least the 40-50% of cases and show an extremely variable long term survival, ranging from 20-70%. Aims. The aim of the study is to provide a prognostic scoring system, to better define the disease-risk in AML patients with NK and to optimally address the issue of post-induction therapy. **Methods.** We retrospectively analyzed 420 AML patients with NK (NK-AML) consecutively treated from 1990 to 2005. Induction regimen was Fludarabine-based in 201 patients (67%) and ICE/DCE in 159 cases. After the first consolidation, patients were addressed to intensification therapy including allogeneic-SCT if aged less than 45 yrs, with at least 2), with a median DFS of 115, 11 and 8, r up the score of each independent variable.

**Results.** The prognostic score for each patient was calculated by totalling and secondary AML and 2 for no response to the first induction regimen. The expression of P2X7, P2X4, P2Y1, P2Y2, P2Y4 receptors. The expression of P2X7, P2X4, P2Y1 was crucial for the protein level. Simulation of AML cells was significantly inhibited by the addition of ATP and, to a higher extent, by the stable analogs INS415 and INS973. We also observed a pronounced inhibitory effect of triphosphate nucleotides on blast spontaneous migration and in response to CXCL12. To assess the activity of nucleotides on AML cell migration in vivo, NOD/SCID/Gamma-Null mice were sub-lethally irradiated and intravenously injected with human AML cells incubated with nucleotides or their analogues. Xenotransplant experiments demonstrated that the homing and the engraftment capacity of human AML cells to murine bone marrow was significantly inhibited by pre-treatment with ATP, UTP and INS415 and INS973 analogues. Thus, our data show that purinergic signaling modulates leukemic cells in a opposite way than normal cells. Characterization of P2R expression and function in leukemia may help the better understanding of the mechanism of neoplastic transformation and tumor progression.

**P028**

**P2 RECEPTORS ARE EXPRESSED ON ACUTE MYELOBLASTIC LEUKEMIA CELLS AND THEIR STIMULATION MODULATES LEUKEMIA CELLS FUNCTION**

Salvestrini V.,1 Gulinielli S.,2 Caione L.,1 Migliardi G.,1 Pacibello W.,1 Ferrari D.,2 Di Virgilio F.1 Lemoli R.M.1

1Institute of Haematology, Department of Hematology and Oncological Sciences “L. & A. Seràgnoli”, University of Bologna, Bologna. 2Dept. of Experimental and Diagnostic Medicine, Section of General Pathology and Interdisciplinary Center for the Study of Inflammation (ICSI), University of Ferrara, Ferrara. 3Department of Oncological Sciences, Laboratory of Clinical Oncology, University of Torino Medical School, Institute for Cancer Research and Treatment, Candelo, Torino, Italy

Extracellular nucleotides ATP and UTP are emerging as ubiquitous molecules involved in a wide variety of biological responses and their biological effects are mediated by specific plasma membrane receptors, P2 receptors (P2R). Previously, we showed that extracellular nucleotides can stimulate the proliferation and engraftment potential of normal human hematopoietic stem cells. In this study, we assessed whether P2R are expressed on acute myeloblastic leukemia (AML) cells and whether their engagement modulates leukemic cell functions. By RT-PCR we found in AML the mRNA expression of P2X1, P2X3, P2X4, P2X5, P2X6, P2X7, P2X1, P2Y2, P2Y4 receptors. The expression of P2X7, P2X4, P2Y1 was crucial for the protein level. Simulation of AML cells was significantly inhibited by the addition of ATP and, to a higher extent, by the stable analogs INS415 and INS973. We also observed a pronounced inhibitory effect of triphosphate nucleotides on blast spontaneous migration and in response to CXCL12. To assess the activity of nucleotides on AML cell migration in vivo, NOD/SCID/Gamma-Null mice were sub-lethally irradiated and intravenously injected with human AML cells incubated with nucleotides or their analogues. Xenotransplant experiments demonstrated that the homing and the engraftment capacity of human AML cells to murine bone marrow was significantly inhibited by pre-treatment with ATP, UTP and INS415 and INS973 analogues. Thus, our data show that purinergic signaling modulates leukemic cells in a opposite way than normal cells. Characterization of P2R expression and function in leukemia may help the better understanding of the mechanism of neoplastic transformation and tumor progression.

**P029**

**WILMS’ TUMOR 1 (WT1) MUTATIONS IN NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA**

Agueli C.,1 Civilegto L.,1 La Rosa M.,1 Dagnino L.,1 Salemi D.1, Bica M.G.,1 Marfia A.,1 Prisinzano F.,1 Cascio L.,1 Mitra M.E.2, Floridia P.M.3, Russo M.,2 Fabbiani E.3, Scimé R.3, Santoro A.3

1Division of Ematologia con UTMO , A.O. V. Cervello, Palermo; 2Division of Ematologia A.O. Universitaria Policlinico “Paolo Giaccone” Palermo; 3Division of Ematologia P.O. “S. Vincenzo” Taranto (ME), Italy

**Introduction.** Acute myeloid leukemia (AML) is a heterogeneous disease characterized by different recurrent chromosomal aberrations that determine the current risk-group classification. In adult AML approximately 40-50% of cases at diagnosis cannot be characterized by karyotypic aberrations. Several molecular aberrations have been identified in this subgroup, such as internal tandem duplications of the FLT3 gene (FLT3/ITD), mutations in NPM1 and CEBPa. The WT1 gene is known to be overexpressed in myeloid leukemias, and is therefore utilized as a marker for minimal residual disease detection. The gene encodes for a zinc-finger transcription factor involved in the regulation of growth and differentiation. Recently WT1 mutations have been identified in ~10% of adult AML with normal karyotype (NK-AML), and their association with unfavourable prognosis is controversial. To determine the role of WT1 aberrations in our patients, we searched for these aberrations in a well-characterized cohort of adult de novo AML patients Results and conclusion: Pre-treatment samples from all patients were studied by

**Poster**

non-hematologic toxicities included oral mucositis and diarrhea. No treatment-related cardiotoxicity or cerebellar toxicity was observed. Median overall survival duration was 4 months (range 1-30); at 10 months, the survival rate was 32%. Median relapse free survival duration was 8 months (range 4.5-29). In conclusion, our data support the use of GO in combination with conventional salvage chemotherapy in this very high risk category of patients and suggest that, for responders, allo-HSCT is feasible.